Prostate Cancer CNA Detection for Aggressive Progression Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to reliably distinguish between aggressive and non-aggressive prostate cancer at early stages, leading to overtreatment of many patients and undertreatment of others.
Innovation Solution
A method involving the detection of copy number alterations (CNAs) in specific genes such as CHD1, PTEN, CDKN1B, BRCA2, RB1, USP10, SERPINF1, TP53, SERPINB5, and MYC in genomic DNA from prostate cancer biological samples, using a probe panel to predict metastatic/lethal cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current diagnostic methods are used to distinguish between aggressive and non-aggressive prostate cancer, then treatment decisions can be made, but the ability to reliably distinguish between the two types at early stages is insufficient, leading to overtreatment of many patients and undertreatment of others
Solution Approach 1:
The diagnostic approach is segmented into multiple components: detection of copy number alterations in specific genes (CHD1, PTEN, CDKN1B, BRCA2, RB1, USP10, SERPINF1, TP53, SERPINB5, MYC), integration with clinical risk stratification, and generation of personalized risk scores. This segmentation allows for more reliable distinction between aggressive and non-aggressive cancer types by analyzing multiple genetic markers simultaneously rather than relying on a single diagnostic tool.
Solution Approach 2:
The patent introduces an intermediary analytical system that processes genomic data from biological samples and integrates it with clinical information. This intermediary system generates predictive models and risk stratification categories that mediate between raw genetic data and treatment decisions, improving the reliability of cancer aggressiveness assessment while reducing information loss.
2Measurement precision
If more comprehensive genetic testing is performed to improve prediction accuracy, then the ability to predict metastatic/lethal cancer improves, but the complexity of the testing methodology increases
Solution Approach 1:
The comprehensive genetic testing is segmented into targeted analysis of specific genes known to be involved in prostate cancer progression (CHD1, PTEN, CDKN1B, BRCA2, RB1, USP10, SERPINF1, TP53, SERPINB5, MYC). By focusing on these specific gene regions rather than performing whole-genome sequencing, the methodology achieves high prediction precision while managing complexity through targeted rather than comprehensive scanning.
Solution Approach 2:
The testing methodology applies local quality by concentrating analytical resources on specific genomic regions with known prognostic significance. The probe panel is designed to specifically detect copy number alterations in these critical genes, allowing high-precision prediction for the most relevant cancer characteristics without the complexity of analyzing every gene in the genome.
Data Source
AI summary
Methods and materials for predicting prostate cancer progression are provided. Such methods may include obtaining from the subject a biological sample from a prostate cancer; isolating genomic DNA from the biological sample; determining copy number alterations (CNAs) in one or more genes selected from the group consisting of: CHD1, PTEN, CDKN1B, BRCA2, RB1, USP10, SERPINF1, TP53, SERPINB5 and MYC in the genomic DNA; and treating the subject with an anticancer agent based on the CNAs of the one or more genes.